back to search abstracts online

Monday February 1,1999	Tuesday February 2, 1999	Wednesday February 3,1999	Thursday February 4,1999
Quantification of d4T Triphosphate (d4TTP) in ZDV Naive and ZDV Experienced HIV Infected Individuals by an Enzymatic Assay Continued lamivudine (3TC) vs delavirdine (DLV) in combination with indinavir (IDV) and zidovudine (ZDV) or stavudine (d4T) in 3TC-experienced patients. ACTG 364: Virologic Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFZ) in Combination with New Nucleoside Analogs in Nucleoside Experienced Subjects (subj). Randomized Trial of Abacavir (ABC) & Nelfinavir (NFV) in Combination with Efavirenz (EFV) & Adefovir Dipivoxil (ADV) as Salvage Therapy in Patients with Virologic Failure Receiving Indinavir (IDV). Placebo (PLC)-Controlled, Multicenter Trial of Adefovir Dipivoxil (ADV) in Patients (Pt) with HIV Disease. Virologic Failure During Combination Therapy with CRIXIVAN and RT Inhibitors Is Often Associated with Expression of Resistance-Associated Mutations in RT Only. Virologic Failure, Resistance and Plasma Drug Measurements in Induction Maintenance Therapy Trial (Anrs 072, Trilege). Sustained CD4 T Cell Response after Virologic Failure of Protease Inhibitor Based Regimens: Correlation between CD4 and Viral Load Response after Two Years of Therapy. Quantifying Residual HIV-1 Replication and Decay of the Latent Reservoir in Patients on Seemingly Effective Combination Antiretroviral Therapy. Effect of Interleukin-2 in Diminution of a Pool of Latently Infected, Resting CD4+ T Cells in HIV-1 Infected Patients Receiving Highly Active Antiretroviral Therapy Overcoming 70 Million Years of Evolution: Developing a Transgenic Mouse Model for HIV-1 Infection. HIV-1 and [leo]-Chemokine Inhibitory Activities of Anti-CCR5 Antibodies Map to Distinct CCR5 Epitopes. HIV-1 Entry into Macrophages through CXCR4 or CCR5: Two Mechanisms of Dual-Tropism for HIV-1 Primary Isolates CD4-dependent and independent infection by primary HIV-1 and HIV-2 strains: Effect of coreceptor-use and influence on the infection of primary human fetal brain cultures Dissection of CCR5 Chemokine and Coreceptor Function and Identification of Distinct Conformational States by Monoclonal Antibodies. Use of coreceptors other than CCR5 by non-syncytium including adult and pediatric isolates of HIV-1 is rare in vitro. CD4/Coreceptor Interactions of Individual Subunits within the HIV Env Oligomer: Evidence Based on Complementation between Different Env Mutants. Enhancement of Human Immunodeficiency Virus Type 1 Infection by RANTES Is Independent of the Mechanism of Virus-Cell Fusion Resistance to a Drug Blocking Human Immunodefiency Virus Type-1 is Conferred by gp41. Recruitment of Cyclin T/P-TEFb is Necessary and Sufficient for Transactivation of the HIV-1 long terminal repeat. Role of Matrix in HIV-1 Replication HIV-1 Nef Activates PAK Kinase in Infected Human Primary Macrophages. A Dileucine-Based Sorting Motif within Nef of HIV-1 is Required for Optimal Viral Infectivity and CD4 Downregulation. Interaction of HIV-1 Vpr with the Cell Cycle. Interaction of Vpr with Uracil DNA Glycosylase Influences the In Vivo Mutation Rate of Human Immunodeficiency Virus Type 1. Deletions Within the Dimerization Initiation Site of HIV-1 Can be Compensated by Three Distinct Point Mutations Within Gag. Modulation of Gene Expression as Monitored by High-Density Oligonucleotide Arrays for the Inoculation of HIV-1 upon T Cells. Increased Removal of Incorporated AZTMP through Dinucleoside Polyphosphate Synthesis by Reverse Transcriptase from AZT-Resistant HIV-1 Identification and Characterization of Cellular Genes Supporting HIV-1 Life Cycle. Transcription Factors Oct-2 and GATA1 Upregulate CCR5 Promoter Activity The Chemokine Receptor CXCR-4 is down regulated in HIV-infected individuals and after in vitro HIV infection. Upregulation of CD4 and CXCR4 Expression on CD40-Activated B Lymphocytes Correlates with Susceptibility to CXCR4-Using Strains of HIV-1. Differential Role of Th1 And Th2 Cells as Targets of HIV Replication. Usage of CXCR4 Determines a Post-Entry Restriction of Viral Spreading. Central Role of CCR5 as a Coreceptor in Tissue Infection by HIV-1 The Formation of a Complex Between CXCR4, CD4 and X4 HIV-1 Envelope Glycoprotein is Inhibited in Resistant to Infection and Fusion Promonocytic U937 Cells. CCR5 Coreceptor Utilization Involves Conserved and Variable V3 Residues of HIV-1 gp120. Staining of Cell Surface CCR5 and CXCR4 with Fluorescently Labeled CD4/Env Complexes. SDF-1 Derived Peptides Blocking HIV Entry via CXCR4. Effect of Mutations in the Second Extracellular Loop of CXCR4 on HIV-1 Infection. Molecular characterization of Enhancement of CCR5- and CXCR4-Dependent Entry mediated by soluble CD4 V3 Peptides Corresponding to T-tropic HIV-1 Can Directly Bind to CXCR4 and Inhibit T-tropic HIV-1 Infection Differentiation of monocytes to macrophages but not to immature and mature dendritic cells leads to a high level of HIV-1_{BaL} production, despite of a low level of chemokine receptor, CCR5 Ability to Use CCR5 and CCR3 Gives HIV Isolates a Replication Advantage in Macrophages Tissue Macrophages Release [leo]-chemokines Which Block HIV-1 Infection When Exposed To Sulphated Dextrins. CXCR4-Specific Strains of HIV-1 May Be Preferentially Eliminated During Antiviral Therapy. Population Genetics Suggests Interactions Between CD4 and CCR5 in the Natural Host of SIV Cells Producing Cytokines and Chemokines in HIV-Replicating Lymph Nodes Cytokine Response Following T Cell Activation in HIV-Infected Children. Regulation of CXCR4 in T Lymphocytes CXCR4 Tropism Is Sufficient to Trigger CD4+ T Cell Depletion in HIV-1-infected Human Lymphoid Tissue Biological Consequences of Chemokine Receptor Polarization on T_{H}1 AND T_{H}2 Cells From Individuals Wild-Type for CCR5 or Homozygous for the D32 ccr5 Allele. HIV-1 Inhibits Macrophage-Dependent CC-Chemokine Production by T Cells via a Mechanism Involving Induction of TGFû and Downregulation of B7-1 Expression. Differential Effects of IL-4 and TNFa on HIV-1 Expression Depend on Coreceptor Usage The Mannose Receptor and CCR5 are Involved in IFN-a Induction by M-Tropic HIV-1. IL-13 Complements with TNF-a to Inhibit Dual Tropic HIV infection of Primary Macrophages by Reducing Surface Expression of CD4, CCR5, CXCR4 and Post-fusion Viral Transcription. Cytokine Effects on CD40 Ligand Stimulation of Macrophages to Produce HIV-Suppressive [unknown character]-Chemokines. The Antiviral Activity of Recombinant CD40L: A Role for Caspase-3 Processing of Interleukin-16. Interleukin-16 (IL-16) Inhibits HIV Replication in Cells from Infected Subjects and Serum IL-16 levels Drop with Disease Progression Constitutive Activation of a Truncated STAT5 Isoform upon HIV Infection in Vivo. The Chemokines IP-10 and Lymphotactin Enhance HIV-1 Long Terminal Repeat Mediated Gene Expression in Monocytic Cells. Chemokine Regulation of HIV-GP120-Induced Human B Lymphocyte Function by SDF-1 Via a TH2-Type Response. Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication in Cytokine Induced CD4+ T Helper 1 (Th1)- and Th2-type Conditions Chemokines and HIV Coat Proteins Inhibit the Development of Langerhans Cells from Peripheral Blood Monocytes and Bone Marrow Precursors. Quantification of CD4, CCR5, CXCR4, and STRL33 levels on Differentially Conditioned Monocyte-Derived Macrophages, Various Subsets of Peripheral Blood Leukocytes and CD34+ Bone Marrow Progenitor Cells. Inhibition of HIV-1 Early Viral Life Cycle Events by CD8+ Cell Supernatant Treatment During Primary HIV Infection Stabilizes the T-Cell Receptor Repertoire in CD8+ Memory T Cells. Phenotypic Identification of CD4 and CD8 Cytotoxic T Lymphocytes in TCR V Beta Expansions in Primary HIV-1 Infection. Impact of HAART on the Diversity of the TCR û Chain Repertoire and the Persistence of HIV-Specific CTL Responses During and Following Primary HIV Infection. Dynamic Changes in an Activated CD8 Cell Subset in Response to Fluctuations in Viral Load During Acute Primary HIV Infection and Subsequent Therapy. Differential T Lymphocyte Responses in Acute HIV Infection: a Comparison of Lymph Node and Blood. Conformationally-intact inactivated SIV virions as an antigen to monitor specific proliferative responses to SIV. Symptomatic Primary HIV-1 Infection (PHI): Correlation with Risk Factors, Viremia and T cell Subset. Meta-Analysis of Host Genetic Effects on HIV Disease Progression Cofactors for HIV disease progression in a cohort of homosexual men with well-defined HIV seroconversion dates. Immunological and Virological Characterization of Individuals with Long-Term Non-progressive HIV-1 Infection in a Hemophilia Cohort. Interaction of Chemokine Receptor Polymorphisms and HIV Disease Progression. Evolution of Coreceptor Use During Progression in the Absence of SI HIV-1 and During Transition from NSI to SI HIV-1 Phenotype Polymorphisms of Genes in HLA Class I and CCR Regions Strongly Predict HIV Viral Load 1 Year after Seroconversion in the Multicenter AIDS Cohort Study (MACS). Levels of CCR5 expressed on antigen presenting cells from wt-CCR5 homozygous and D32-CCR5 heterozygous individuals are not a limiting factor for HIV-1 infection. Upregulation of CCR5 gene expression in PBMC from HIV-1 infected Patients: correlation with disease progression. CCR5 and SDF-1 Polymorphism in HIV-1 Infected Individuals. Influence of CCR5, CCR2 and SDF-1 Genetic Polymorphisms on HIV-1 Disease Progression in Childhood. Global Distribution and Origin of the CCR2-64I/CCR5-59653-T HIV Disease-Protective Haplotype. Genetic Factors Affecting the Risk of Heterosexual HIV Transmission. Modeling the Influence of Host Genetic Factors in HIV Epidemics. Incubation Time of Primary HIV Infection (PHI): relationship with disease progression. Short-term Prognostic Value of Plasma HIV RNA in Late-stage HIV Infection. Soluble Tumor Necrosis Factor Receptor Type II as Prognostic Marker of AIDS in HIV Patients with Advanced Immunodepression. Nef Protein of HIV-1 Is Attachable for a Cloned 32 kDa Cellular Protein Bearing PK activity Utilization of an Epitope to Determine the Ratio of Gag and Vpr Present in Virus Paritcles Directed by HIV-1. HIV-1 Viral Protein R Mediates Enhanced Replication in Primary Human CD4+ T-cells by Arresting Cells in the G2 Phase of the Cell Cycle. Phosphorylation of HIV-1 Vpr and Effect on Vpr Biological Functions. Mutational Analysis of Vpr-induced G2 Arrest, Nuclear Localization and Cell Death in Fission Yeast (Schizosaccharomyces pombe) Functional Variations of HIV-1 Vpr in Laboratory Viral Strains. The Role of Viral Protein U in HIV-1 Particle Assembly. Amino Acids in CD4 Cytoplasmic Domain which Determine the Sensitivity for Vpu-Dependent Proteasomal Degradation. H-beta TrCP, which Promotes Vpu-mediated CD4 Degradation, is Involved in Proteolysis of Cellular Phosphoproteins by the Proteasome. The High Rate of HIV-1 Recombination Indicates that Both Viral RNAs are Utilized During HIV-1 Reverse Transcription. The Role of Pr55gag in The Genomic Placement of tRNAlys3 in HIV-1. Conditional Replication of HIV-1 by Providing a tRNA in trans Effect of the M184V Substitution in RT on HIV Genetic Variation. Two Distinct Point Mutations in the U5 Region of the PBS Can Eliminate an Important Pause Site Involved in Initiation of HIV-1 Reverse Transcription. Decreased Processivity of HIV-1 Reverse-Transcriptase Containing ddI-Selected Mutation Leu74Val. Synthesis and Anti-HIV Activity of 2'-Fluoro-2',3'-unsaturated L-Nucleoside (L-d4N) Analogs Antiviral Activity and Resistance Profile of Phosphazid - A Novel Prodrug of AZT. Antiretroviral Activity, Safety and Metabolism of BCH-10652, a New Nucleoside Analogue. Single-dose Pharmacokinetics (PK) of BCH-10652 in Healthy, Adult Volunteers. Novel mutations in HIV-1 reverse transcriptase selected for by 2',3'-dideoxy, 2',3'-didehydro-û-5-fluorocytidine, a potent inhibitor of HIV-1. Abacavir, d4T, ZDV, ddI, and 3TC Differentially Affect Viral Spread in Brain Tissue of SCID Mice with HIV-1-Encephalitis. GW420867X: A Novel Quinoxaline-Class NNRTI of HIV-1 with Improved Antiviral Properties in the Presence of Human Serum and its Components NNRTI GW420867X: Comparative Evaluation of the In Vitro Resistance Profile GW420867X, a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), Single and Repeat Dose Pharmacokinetics (PK). (-)-Calanolide B - A Novel and Naturally-Occurring Non-Nucleoside Reverse Transcriptase Inhibitor of HIV-1 Resistance Profile And Drug Combination Studies Of An HIV-1 Protease Inhibitor BMS-232632 BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers. The Structure Activity Relationship (SAR) of a Novel Series of HIV Protease Inhibitors (PIs) Define the Level of Similarity Between Drug-Resistant and Wild-Type (WT) Protease. Clinical Safety and Pharmacokinetics of (+)-Calanolide A, A Naturally Occurring NNRTI, in Normal Healthy and HIV-Infected Volunteers Dynamics of HIV Replication in Primary Macrophages and Modulation by Antiviral Drugs. AR177 Inhibits HIV-1 Entry in vivo. A more potential CXCR4-dependent inhibitor, T140 Chemokine CXCR-4 Receptor Blocker, AMD-3100: Clinical and Pre-clinical Studies of Pharmacokinetics and Safety. HIV-1 Selection in Response to Inhibition of Virus Fusion and Entry HIV-1 Replication Kinetics After Perturbation of de novo Infection by T-20 A Potent Fusion Inhibitor. CCR5 Antagonists Either Inhibit HIV-1 Infection of hu-PBL-SCID Mice or Select for CXCR4-Using Variants. Safety and Efficacy of FP-21399 a Novel Fusion Inhibitor- Results of a 48 wk Phase II Study. In Vitro Inhibition of HIV-1 in Peripheral Blood Mononuclear Cells by Met-SDF1. A Novel Hybrid Synthetic Peptide Inhibitor of HIV-1, SIV, and HIV-2 Fusion and Infection In Vitro. Potent Inhibition of HIV-1 Replication In Vitro and In Vivo by a Synthetic Hybrid Peptide Inhibitor of HIV-1, SIV, and HIV-2 Fusion. A Phase I Dose Escalation Trial of PRO 542, A Novel Inhibitor of HIV-1 Entry. Inhibition of HIV-1 by an Anti-Integrase Single-Chain Variable Fragment (SFv): Delivery by SV40 Provides Durable Protection Against HIV-1 and Does Not Require Selection. DNAzyme against a conserved sequence of HIV-1 env Modulation of HIV-1 Frameshift Efficiency: A New Target for Therapeutic Intervention. HIV Regulatory Proteins: Targets of Triciribine? HIV-NAT 003: A Randomized, Open-label, Comparative Trial of AZT/3TC versus AZT/3TC/ddI in Antiretroviral Naive HIV-1 Infected Thai Patients. Second Placebo-Controlled Study in Naive Individuals Confirms the Role of Delavirdine in Higly Active Antiretroviral, Protease-Sparing Treatment. Durable Activity of Ziagen (Abacavir, ABC) Combined with Protease Inhibitors (PI) in Therapy Naive Adults. Combination Ziagen (Abacavir, ABC)/Amprenavir (141, APV-USAN) Therapy in HIV-1 Infected Antiretroviral Naive Subjects with CD4+ Counts 400 cells/µl and Plasma HIV-1 RNA 5000 copies/mL. MIRO: a Randomized Trial of Maintenance Therapy with or without Protease Inhibitors after 4 Months of Triple or Quadruple Induction Therapy An Open Randomized Study Comparing d4T plus ddI and Nevirapine (QD) vs d4T plus ddI and Nevirapine (BID) in Antiretroviral Naive Chronic HIV-1 Infected Patients in Very Early Stages (Spanish SCAN Study) Quick Viral Load Rebound After One Year Of Successful HAART In Chronic HIV-1 Infected Patients In Very Early Stages. Iris Study: Ritonavir/Saquinavir (RTV-SQV) versus Indinavir (IDV) in Association with NRTI: One Year Follow-up. Efficacy and Safety of BID Firstline Ritonavir/Indinavir Plus Double Nucleoside Combination Therapy in HIV-infected Individuals The VIRGO Trial: d4T/ddI (qd)/nevirapine (bid or qd) in Antiretroviral-Naive HIV-1-Infected Patients - a Convenient and Potent Regimen. Ozcombo I: Control of HIV Replication in Treatment Naive Patients in a Randomised Trial of HAART Initial HIV-1 Clearance Rate in Antiretroviral Naive Patients After Antiretroviral Therapy With D4T plus DDI and either NVP, IDV, or 3TC. Remarkably Sustained Virologic Response After Indinavir Addition to Suboptimal AZT/3TC and d4T/3TC Therapy: 72 Weeks Follow-Up. The long term response to combination therapy commenced early in HIV infection: 3 year follow-up. What's happened since Vancouver? Viral suppression and CD4-cell recovery in patients with primary HIV-1 infection treated with HAART Clearance of HIV Proviral Load in Circulating Mononuclear Cells in Patients with Acute/Early Infection Receiving Aggressive Antiretroviral Therapy. Potent, Durable Combination Therapy with Abacavir, Amprenavir, and ZDV/3TC in Subjects Acutely & Chronically Infected with HIV-1. Highly Active Antiretroviral Therapy (HAART) vs. Non-HAART for Primary HIV Infection (PHIV). Diagnosis and prediction of HIV protease inhibitor (PI)-induced lipodystrophy and impaired glucose tolerance. Frequency of Lipodystrophy and Factors Associated with Glucose/Lipid Abnormalities in a Cohort of 650 Patients Treated by Protease Inhibitors. Effects of Protease Inhibitor Use on Hyperglycemia and Hyperlipidemia: A Five Year Analysis. Prevalence And Risk Factors For Hyperglycemia, Dyslipidemia, And Coronary Disease Among Hiv-Infected Patients On Initial Protease Inhibitor Therapy Dyslipidemia and Insulin Resistance in HIV-infected Patients Treated with Reverse Transcriptase Inhibitors Alone and in Combination with Protease Inhibitors. Lipid Abnormalities and Body Composition Alterations in Progressive Stages of the HIV/HAART Associated Lipodystrophy (HAL) Syndrome. Lipid Evaluation and Glucose Metabolism in HIV-1 Positive Patients Treated with Protease Inhibitors. Changes in Serum Cholesterol and Triglyceride Levels in Patients Treated with Indinavir or NRTIs. The Prevalence of Hypertriglyceridemia in HIV Infected Individuals Who Have Been Exposed to Various Antiretroviral Drug Classes Since January 1996. High Prevalence of Impaired Glucose Tolerance Prior to Initiating Protease Inhibitor Therapy. HIV-Related Truncal Obesity: a Comparison of Physician and Patient Diagnoses in the SALSA (Self-Ascertained Lipodystrophy Syndrome Assessment) Questionnaire. Lipodystrophy Index by Anthropometric Parameters (LIAP): An Approach to the Diagnosis of Lipodystrophy by Measurable Parameters in Patients Taking Protease Inhibitors. A Syndrome of Lipodystrophy in Patients Receiving a Stable Nucleoside-Analogue Therapy. Lypodystrophy Syndrome (LS) In Patients On Reverse Transcriptase Inhibitors. Potential Adverse Experiences Associated with Efavirenz (EFV, SUSTIVATM) in Adults. Increased Morbidity from Severe Coronary Heart Disease in HIV-Patients Receiving Protease Inhibitors. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease Among HIV Positive Patients? No Association Observed Between Indinavir Therapy for HIV/AIDS and Myocardial Infarction in 4 Clinical Trials with 2,825 Subjects Relationship Between Body Fat Distribution, Lipoprotein Levels and Fasting Insulin in HIV+ Women Treated with Protease Inhibitors (PI). Nucleoside Reverse Transcriptase Inhibitors Associated Fat Redistribution in HIV-Infected Women Undergoing Combined Antiretroviral Therapy. Association of Diabetes and Protease Inhibitor Use In A Large Natural History Cohort of HIV+ Women. Changes in Body Shape during PI Therapy in HIV+ Women. Women First: Durable Response with Dual Protease Inhibitor Therapy Without Significant Elevations in Lipids. Are the Decreased Lipolytic Enzyme Activities Responsible for the Hypertriglyceridemia in PI-Treated Patients ? Indinavir Enhances Retinoic Acid Signaling: Nelfinavir, Saquinavir, and Ritonavir Inhibit Retinoid Effects in vitro. HIV Protease Inhibitors Block Adipogenesis and Increase Lipolysis in vitro. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir. Management of Indinavir-associated metabolic changes by substitution with Efavirenz in virologically controlled HIV+ persons Reversion of Lipodistrophy after Switching HIV-1 Protease Inhibitors to Nevrirapine. EXPERIENCE WITH THE NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINES FOR THE IDENTIFICATION AND TREATMENT OF PROTEASE INHIBITOR RELATED LIPID ABNORMALITIES: RESULTS OF A PROSPECTIVE STUDY Effects of Metformin on Insulin Resistance and Central Adiposity in Patients Receiving Effective Protease Inhibitor (PI) Therapy. Effects of the PPAR-g Activator Troglitazone on Protease Inhibitor Associated Peripheral Insulin Resistance. Incidence of Body Habitus Changes In a Cohort of 725 HIV-Infected Patients. The Effect of Recombinant Human Growth Hormone on Protease-Inhibitor-Associated Fat Maldistribution Syndrome. Serious Adverse Events (SAE) in a Prospective Cohort of HIV-infected Adults Started on Protease Inhibitor Therapy (ANRS EP11 Study) Combining Ritonavir and Indinavir Decreases IDV Associated Nephrolithiasis. Safety of Adefovir Dipivoxil (ADV) and Incidence of Proximal Renal Tubular Disorder (PRTD) in a Placebo (PLC)-Controlled Trial in Patients (Pt) with Advanced HIV Disease. Bone Mineral Density Diminution in HIV Patients Treated with HAART. Avascular Necrosis In HIV + Patients A Potential Link To Protease Inhibitors Ingrown toenails and indinavir: case-control study demonstrates strong relationship. Gender Differences in Nevirapine Rash Mode of Delivery and Postpartum Morbidity Among HIV-Infected Women: The Women and Infants Transmission Study (WITS). Complications According to Mode of Delivery Among HIV-positive Women with CD4 Counts < 500. Risk Factors for Adverse Pregnancy Outcomes (APO) in HIV-Infected Pregnant Women in PACTG 185. A Review of Protease Inhibitors (PI) Use in 89 Pregnancies Maternal and Infant Outcomes with Highly Active Antiretroviral Therapy During Pregnancy Safety and Tolerance of Ritonavir in Combination with Lamivudine and Zidovudine in HIV-1 Infected Pregnant Women and their Infants. Continued Decline in Morbidity and Mortality Among Patients with Advanced HIV Infection Receiving Highly Active Antiretroviral Therapy (HAART) Which Opportunistic Illnesses Occur in the Era of HAART and at What CD4 Cell Counts? Differential Effect of HAART on Development of Opportunistic Illness and Death in Clinical Practice. The Risk for Pneumocystis carinii Pneumonia (PCP) and Disseminated Nontuberculous Mycobacteriosis (dMb) After an Antiretroviral Therapy (ART) Associated Increase in the CD4+ T-lymphocyte Count Effect of HAART on the Incidence of Bacterial Pneumonia in Patients with Advanced HIV Infection. CHARACTERISTICS OF HOSPITALIZED HIV-INFECTED PATIENTS FOLLOWING THE AVAILABILITY OF HAART Changing Epidemiology of Hospital Admissions Among HIV + Patients. Comparison of Patterns of Care and Outcomes of HIV-Related Pneumocystis carinii Pneumonia Among Sexually Acquired HIV, Intravenous Drug and Crack Cocaine Users. Corticosteroid Utilization and Outcomes in HIV Associated Pneumocystis carinii Pneumonia: Three-fold Higher Mortality Among Severely Ill Patients When Corticosteroids Given by CDC Guidelines. Intolerance (INT) to atovaquone(ATQ) and dapsone(DAP) & the impact of prior type of INT to trimethoprim/ sulfamethoxazole (TMS). Effects of Angiogenesis and Protease Inhibitors on Microsporidia Growth In Vitro. A Simian Immunodeficiency Virus-Infected Macaque Model of Enterocytozoon bieneusiInfection in AIDS. Block in the Generation of Dihydrotestosterone from Testosterone in Patients with Weight Loss. Improvement in Immune Status in Wasting AIDS Patient by Providing Muscle and Immune Tissue-Specific Nutrition. Effects of Pharmacologic Doses of Nandrolone Decanoate and Progressive Resistance Training During HIV Immunodeficiency. Emergence of Oral Warts in the HAART Era. Incidence and Predictors of Oral Mucosal Lesions in the Women's Interagency HIV Study (WIHS). Improved Survival with Correction of Anemia in HIV Disease. Phase-I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor for HIV-associated Thrombocytopenia. HIV-1 Genetic Subtype A/B Recombinant Strain Causing an Explosive IDU Epidemic in Kaliningrad. Molecular Epidemiology and Evolutionary History of HIV-1 Subtype F Viruses from Romania, South America and Central Africa Evolution of NSI/R5 Isolates During HIV-1 A or A/E Infections in Africa and Asia. HIV-1 Subtypes B' and E: Associated Clinical, Immunologic, and Risk Characteristics in Bangkok, Thailand. Molecular Epidemiology of HIV-1 in South Vietnam : an Update. Human Immunodeficiency Virus Type 1 (HIV-1) Subtypes in Injecting Drug Users (IDUs) and Their Wives in Manipur, India Molecular Epidemiology of HIV-1 in Argentina: Predominance of Subtype F Infections in a Heterosexual Population. Quantification of HIV-1 Group M and O Viruses with Comparable Efficiency: Development of an LTR-based NASBA. Efficient Quantification of HIV-1 Group M (Subtypes A-G) and Group O by the Abbott LCx HIV RNA Quantitative Assay Sensitivity, Linear Range and Subtype Performance of an Automated, RT-PCR Viral Load Test for HIV-1. Variable Reactivity of Genetic HIV-2 Subtypes in a Prototype PCR-based vRNA Quantitative Assay. Characterization of an International HIV-1 Subtype Panel for Future Use as Standards and Reference Strains. Evaluation of a Rapid Immunoassay for Detection and Differentiation of HIV-1 Group M, Group O, and HIV-2 Infections Use of Recombinant gp120s (rgp120s) Produced by Sendai Virus (SeV) Based Expression Technology for Highly-Sensitive and Specific Serologic Determination of HIV-1 Subtypes Diversity in the Immunodominant Epitopes of Envelope gp41 of HIV-1 Group M

© 6th Conference on Retroviruses and Opportunistic Infections,
Foundation for Retrovirology and Human Health

This site designed and maintained by:
© Medical Consumer Media. All Rights Reserved.
For inquiries, contact: retroinfo@medcm.com

The broadcasts of selected invited sessions from the 6th Conference on Retroviruses and Opportunistic Infections are for individual, non-commercial use only. No portion of this site (including speakers' audiotrack, slides, and abstracts) may be copied, reproduced, or rebroadcast without the express advanced written permission of the speaker(s) and the Conference Secretariat.